---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-015546"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T23:09:38.806869+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nektar reports Q4 2022 net loss $59.7M; cash $505M, runway through mid-2025

## Summary
- Q4 2022 revenue $22.0M (down from $25.0M YoY); full-year revenue $92.1M (down from $101.9M).
- Q4 net loss $59.7M ($0.32 loss per share) vs $145.6M ($0.79) in Q4 2021; full-year net loss $368.2M ($1.97) vs $523.8M ($2.86).
- Cash and investments $505.0M at Dec 31, 2022, down from $798.8M; CEO expects runway through at least mid-2025 with additional cost cuts.
- R&D expense fell to $34.7M in Q4 (from $99.6M) due to wind down of bempegaldesleukin program; restructuring costs $11.6M in Q4.
- On Feb 23, 2023, announced Phase 2 topline data for rezpegaldesleukin in SLE; no Q4 earnings call held.

## SEC filing metadata
- accession: 0001213900-23-015546
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390023015546/0001213900-23-015546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390023015546/ea174444-8k_nektartherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-015546
- JSON: https://secwatch.observer/filing/0001213900-23-015546.json
- Plain text: https://secwatch.observer/filing/0001213900-23-015546.txt

## Key facts
- Earnings Releases
  NEKTAR THERAPEUTICS reported the quarter and year ended December 31, 2022 results: revenue Revenue in the fourth quarter of 2022 was $22.0 million, net income Net loss for the fourth quarter of 2022 was $59.7 million, EPS $0.32 basic and diluted loss per share.
  - Period: the quarter and year ended December 31, 2022
  - Revenue: Revenue in the fourth quarter of 2022 was $22.0 million
  - Net income: Net loss for the fourth quarter of 2022 was $59.7 million
  - EPS: $0.32 basic and diluted loss per share
  - Result: reported results
  source text: On February 28, 2023, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390023015546/0001213900-23-015546-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.